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Neurite outgrowtha b s t r a c t
The pituitary adenylate cyclase-activating polypeptide (PACAP) is a trophic neuropeptide that pro-
motes cell survival and neuritogenesis in the central and peripheral nervous system. Our previous
transcriptomic studies revealed the down-regulation of the cytokine tumor necrosis factor (TNF)
during PACAP-induced PC12 cell differentiation. Here we show that TNF is constitutively expressed
in PC12 cells in a manner dependent on NF-jB transcription factor, and that PACAP rapidly inhibits
TNF expression and secretion. The inhibition occurs through suppression of RelB subunit of NF-jB,
and is likely to prevent the deleterious effects of the cytokine on survival and neurite outgrowth
during PC12 cell differentiation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Tumor necrosis factor (TNF) is a pro-inﬂammatory cytokinePituitary adenylate cyclase-activating polypeptide (PACAP) is a
38 amino-acid, a-amidated neuropeptide which exerts various tro-
phic effects in the central and peripheral nervous system, and in
peripheral tissues [1,2]. The various actions of PACAP are mediated
by two types of G-protein-coupled receptors: a PACAP selective
receptor, named PAC1-R, and two PACAP/vasoactive intestinal
polypeptide mutual receptors, named VPAC1-R and VPAC2-R [2].
These receptors activate different signal transduction pathways,
which in turn regulate transcription of genes associated with cell
survival and differentiation, e.g., growth arrest and neurite out-
growth in many neuronal cell types [1]. PACAP has been shown
to induce differentiation of PC12 cells towards a neuronal-like phe-
notype via PAC1 receptor [3,4], thus offering a paradigm to study
the signaling cascades leading to neuro-endocrine cell differentia-
tion induced by a ligand of G protein-coupled receptors.which exerts its biological effects through activation of two types
of receptors, type I (TNF-R1) and type II (TNF-R2) TNF receptors.
At variance with TNF-R2, TNF-R1 possesses a death domain on
its intracellular region which confers to TNF the ability to stimulate
caspase activity and apoptotic cell death [5]. In brain, TNF has been
shown to be involved in different types of injuries and pathologies
[6], and to modulate survival, proliferation and differentiation of
neuronal cells [7,8]. The effects of the cytokine seem to be depen-
dent on the cell type and the expression of the TNF receptor sub-
types [8]. In immune cells, PACAP inhibits production of many
pro-inﬂammatory cytokines including TNF [9]. However, little is
known about TNF involvement in PACAP-induced neuronal or
neuro-endocrine differentiation. In the present study, we showed
that PACAP inhibits TNF gene expression and secretion in order
to promote cell survival and neuritogenesis during PC12 cell
differentiation.
2. Materials and methods
2.1. Drugs
PACAP38 was synthesized by the solid phase methodology














































Fig. 1. Effect of PACAP on TNF expression and release. (A) PC12 cells were treated
with PACAP (100 nM) for the indicated times, and TNF mRNA levels were quantiﬁed
by real-time PCR. Data are expressed as means ± SEM relative to control values
(n = 6). ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001 (Mann–Whitney U test). (B) PC12 cells were treated
with PACAP (100 nM) or left untreated for 6 h. After treatment, the culture medium
was collected and TNF was measured in each condition. Data are expressed as
means ± SEM relative to control values (n = 4). ⁄p < 0.05 (Mann–Whitney U test).
D.-L. Manecka et al. / FEBS Letters 588 (2014) 3008–3014 3009Sigma–Aldrich (Saint-Quentin Fallavier, France) and human
recombinant TNF was purchased from Eurobio (Courtaboeuf,
France).
2.2. Cell culture
Rat pheochromocytoma PC12 cells were obtained from the
European Collection of Cell Culture (ECACC, Salisbury, Wiltshire,
UK) and maintained in Dulbecco’s modiﬁed Eagle medium
(Sigma–Aldrich), supplemented with 10% horse serum (Invitrogen,
Cergy Pontoise, France), 5% fetal bovine serum (Sigma–Aldrich),
2 mM L-glutamine, 100 units/ml penicillin, and 100 lg/ml strepto-
mycin (Invitrogen) at 37 C in 5% CO2 humidiﬁed atmosphere. The
medium was renewed every 2–3 days. Twenty-four h after plating,
differentiation of PC12 cells was initiated by adding PACAP38
(100 nM).
2.3. Animals
C57bl/6J embryos were collected at E16 and ﬁxed in 4% PFA
overnight. On the next day they were rinsed once in PBS and then
soaked for 48 h in 30% sucrose for cryoprotection prior to embed-
ding in OCT and storage at 80 C. 15 lm-thick transverse sections
were cut with a cryostat, mounted on Superfrost + slides, and then
stored at 80 C.
Adult Wistar rats were sacriﬁced by CO2 inhalation in order to
collect the adrenal glands and the brain, which were immediately
frozen on dry ice for RNA extraction.
2.4. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNAwas isolated from PC12 cells, rat adrenal gland and rat
brain using the Tri-Reagent (Sigma–Aldrich). Approximately 1 lg of
total RNA was reverse-transcribed using the ImProm-II™ Reverse
Transcription System (Promega, Charbonnières, France). One tenth
of the reaction mixture was used to quantify TNF and RelB expres-
sion by real-time PCR. Gene-speciﬁc forward and reverse primers
were designed using the Primer Express software (Applied Biosys-
tems) as follows: 50-GGCTGCCCCGACTATGTG-30 and 50-
TGACTTTCTCCTGGTATGAAATGG-30 for TNF; 50-GAACACCGTGTG-
TAACTGCC-30 and 50-ATTCCTTCACCCTCCACCTC-30 for TNF-R1; 50-
GATGAGAAATCCCAGGATGCAGTAGG-30 and 50-TGCTACAGACGTT-
CACGATGCAGG-30 for TNF-R2; 50-CCTGTCTACGACAAGAAGGACA-
30 and 50-TGTGCACGTCAGCTTGAGAA-30 for RelB and, 50-AACTCCCT-
CAAGATTGTCAGCAA-30 and 50-TGGTCATGAGCCCTTCCA-30 for glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) used as a
reference gene. Real-time PCR was carried out in SYBR Green
PCR Master Mix in the presence of 300 nM speciﬁc primers, using
an ABI Prism 7000 apparatus (Applied Biosystems, Norwalk, CT).
The relative efﬁciency of the ampliﬁcation of each gene was
assessed, and the amounts of each mRNA were determined by nor-
malizing against GAPDH mRNA levels using the comparative Ct
method as described by the apparatus manufacturer (Applied Bio-
systems). For regular PCR, a 3-lL sample of the RT reactionwas then
ampliﬁed with ReddyMix PCR Master Mix (AB Gene, UK) using the
appropriate primers in the GeneAmp PCR System 9700 (Applied
Biosystems), in the following conditions: 94 C, 1 min; 30 cycles
of 94 C, 30 s; 52 C, 45 s; 68 C, 1 min; 68 C, and ﬁnally 5 min at
68 C. The PCR products were resolved on a 1.5% agarose gel con-
taining 0.0001% ethidium bromide.
2.5. Cell viability assay
Cell viability was assessed using the MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Brieﬂy, PC12
cells cultured in 100 lL of medium in 96-well culture plates wereincubated with 10 lL of phosphate-buffered saline (PBS) contain-
ing 5 mg/ml MTT for 4 h at 37 C in 5% CO2 atmosphere. Then,
100 lL of a solubilization solution consisting of 50% N,N-dimethyl-
formamide and 20% sodium dodecyl sulfate (SDS), adjusted to pH
4.7 with acetic acid, was added to the culture medium, and the
plates were incubated at 37 C overnight. The absorbance was then
recorded using a microplate reader Bio-tek FL 600 (Bio-tek, Illkirsh,
France). Speciﬁc optical density (DOD570-750) for the MTT prod-
uct was obtained by subtracting the OD value at 750 nm from that
at 570 nm, reﬂecting the number of viable cells.
2.6. Neurite outgrowth measurement
PC12 cells cultured on coverslips in 6-well culture plates were
washed twice with ice-cold PBS, ﬁxed in paraformaldehyde solu-
tion (4% w/v) for 15 min, then permeabilized with Triton X-100
solution (0.1% Triton X-100 in PBS) for 20 min. After a blocking step
of 1 h with 1 mg/ml BSA in PBS, cells were incubated overnight at
4 C with primary antibody directed against alpha-tubulin (Tebu-
bio; Le Perray en Yvelines, France). Immunodetection was per-
formed with FITC-conjugated goat anti-mouse IgG (1:300 dilution).
After mounting, ﬂuorescence was analyzed using a Leica TCS SP2
confocal microscope (Leica Microsystems, Reuil-Malmaison,
France). Neurite analysis was performed using ImageJ software
(National Institutes of Health, USA). Neurite outgrowth was evalu-
ated by calculating the number of processes per cell and measuring
neurite length. Neurite was deﬁned as a cell process >10 lm.
2.7. SiRNA transfection
PC12 cells were transfected with siRNA (Qiagen, Courtaboeuf,
France) by using the Amaxa Nucleofector system and the Cell Line
Nucleofector kit V electroporation method (Lonza, Basel, Switzer-
land) according to the manufacturer’s protocol (program U-029).
To assess the efﬁciency of siRNA-induced knockdown, mRNA and
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quantitative PCR or Western blot.
2.8. Western blot analysis
PC12 cells cultured in 6-well plates (105 cells/well) were lysed
in a buffer containing 10 mM Tris–HCl, pH 7.4, 0.05% Triton X-
100, and 1 mM phenylmethylsulfonyl ﬂuoride. After centrifugation
(12,000g, 15 min), the supernatant was precipitated with 10% tri-
chloroacetic acid and the whole protein precipitate was washed
by ethanol/ether (v/v), and dissolved in electrophoresis-denaturing
buffer. Proteins were quantiﬁed by the Bradford assay (Bio-Rad,
Marnes-la-Coquette, France) to ensure loading of equivalent
amounts from all samples. Extracts were separated by SDS–poly-
acrylamide gel electrophoresis followed by electrotransfer onto
nitrocellulose membranes (Amersham Pharmacia Biotech, Orsay,
France). RelB was detected using a polyclonal antibody (1:1000
dilution) obtained from Santa Cruz Biotechnology (Heidelberg,
Germany), followed by horseradish peroxidase-conjugated second-
ary antibody (1:5000). The antigen–antibody complexes were visu-

















































Fig. 2. Effect of TNF on PACAP-induced differentiation in PC12 cells. (A–D) PC12 cells we
Cell morphology changes were analyzed by immunoﬂuorescence confocal microscopy,
neurite length (C) were determined using confocal macroscopy and ImageJ software.
⁄p < 0.05;⁄⁄p < 0.01; ⁄⁄⁄p < 0.001 (Student’s t-test). Cell viability was assessed using the MT
not signiﬁcant; ⁄p < 0.05; (Mann–Whitney U test). (E) Total RNA from PC12 cells, rat ad
reverse transcriptase and used to amplify by PCR cDNA fragments of TNF-R1 and TNF-Rsystem (Amersham Pharmacia Biotech) and ChemiDoc XRS + Imag-
ing System (Bio-Rad).2.9. Immunohistochemistry
After a saturation step of 45 min in 1% goat normal serum,
diluted in a solution containing 1% BSA and 0.3% Triton X-100 in
PBS at room temperature, mouse sections were incubated over-
night with RelB and tyrosine hydroxylase antibodies (1:200) at
4 C. RelB antibody was obtained from Santa Cruz Biotechnology
(Heidelberg, Germany) and tyrosine hydroxylase antibody was
obtained from Merck Millipore (Guyancourt, France). These pri-
mary antibodies were revealed with secondary anti-rabbit and
anti-mouse IgG Alexa Fluor 488 and 594 (1:300) (Invitrogen).
Slides were counterstained with 1 lg/mL 4,6-diamino-2-phenylin-
dole (DAPI, Sigma–Aldrich) in PBS for 1 min. Negative controls
were performed using secondary antirabbit and antimouse IgG
(1:300) without primary antibodies. In both cases, no immunore-
action was observed. Tissue sections were examined with a Leica
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Fig. 3. Role of NF-jB in PACAP-induced TNF inhibition. (A) PC12 cells were treated with PACAP (100 nM) in the presence or absence of PS-1145 (10 lM) for 24 h. TNF gene
expression was quantiﬁed by real-time PCR. Data are expressed as mean ± SEM relative to control values (n = 4). ⁄p < 0.05; ⁄⁄p < 0.01 (Mann–Whitney U test). (B) Forty-eight
hours after transfection of PC12 cells with control or RelB siRNA, RelB gene expression was quantiﬁed by real-time PCR. Data are expressed as mean ± SEM relative to control
values (n = 4). ⁄p < 0.05; (Mann–Whitney U test). (C) Western blotting of RelB after siRNA treatment. a-Tubulin was used as a loading control. (D) Twenty-four hours after
transfection of PC12 cells with control or RelB siRNA, cells were treated with PACAP (100 nM) for 6 h and TNF mRNA levels were quantiﬁed by real-time PCR. Data are
expressed as means ± SEM relative to control values (n = 4). ⁄p < 0.05; ⁄⁄p < 0.01; (Mann–Whitney U test).
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Results are expressed as means ± standard error of the mean
(SEM). Statistical signiﬁcance was assessed through the non-para-
metric Mann–Whitney test or Student’s t-test. A p value < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. PACAP inhibits TNF production
As a ﬁrst approach to determine the involvement of TNF in the
PACAP effect in PC12 cells, we determined by quantitative PCR anal-
ysis the mRNA levels of the cytokine after treatment with the neu-
ropeptide for different times. PACAP rapidly and strongly inhibited
the expression of the cytokine; the effects being maximal after 6 h
of treatment (Fig. 1A). To assess whether the release of TNF protein
could be affected by PACAP, we used a speciﬁc ELISA to determine
the amounts of the cytokine present in the culture medium after
PACAP treatment. This experiment showed that PACAP also induced
a 40% decrease in TNF secretion (Fig. 1B). These data suggest that
TNF is constitutively expressed in PC12 cells, and that inhibition
of its gene expression and its secretion could be involved in the
PACAP-mediated effects on differentiation of these cells.
3.2. TNF abolishes the differentiating effects of PACAP through TNF-R1
Microscopic examination revealed that the PACAP-induced
morphological changes in PC12 cells are impaired in the presence
of TNF (Fig. 2A). Thus, TNF signiﬁcantly decreased the number of
neurites per cell compared to the effect of PACAP alone (Fig. 2B),
but did not affect neurite length (Fig. 2C). The MTT assay revealed
that the PACAP-elicited increase in cell viability is abolished by co-
treatment with TNF (10 lM) (Fig. 2D). In order to determine which
TNF receptor is expressed in PC12 cells and could therefore be
involved in TNF action in these cells, TNF-R1 and TNF-R2 expres-
sion was examined by PCR. This assay revealed that PC12 cells
express TNF-R1 but not TNF-R2, while both receptors are presentin the rat adrenal gland and brain used as positive controls
(Fig. 2E).
3.3. PACAP-inhibited TNF expression involves the NF-jB pathway
Many reports have linked TNF expression to the NF-jB signaling
pathway [10,11]. Therefore, we evaluated the effect of PS-1145, a
speciﬁcblocker of inhibitor ofNF-jBkinase (IKK), the kinase respon-
sible for NF-jB activation, on TNF gene expression in PACAP-treated
or untreated PC12 cells. In basal condition, we observed an approx-
imately 75% decrease in TNF gene expression in cells treated with
PS-1145 (10 lM) (Fig. 3A), suggesting that the NF-jB pathway
participates in constitutive expression of the TNF gene in PC12
cells. PACAP inhibited TNF gene expression to levels comparable to
those observed with PS-1145 (Fig. 3A). As PACAP and PS-1145 exert
similar effects on TNF mRNA levels and the action of the neuropep-
tide is not modulated by PS-1145 (Fig. 3A), it can be inferred that
PACAP-evoked inhibition of TNF could be mediated by suppression
of NF-jB activity.
As we showed in a previous study that the nuclear translocation
of RelB subunit of NF-jB is reduced by PACAP in PC12 cells [12], we
sought to determine whether this NF-jB subunit could be involved
in the regulation of TNF gene expression by the neuropeptide. We
ﬁrst determined that treatment with a speciﬁc siRNA leads to 86%
decrease in RelB mRNA levels in PC12 cells (Fig. 3B). The efﬁciency
of siRNA-induced knockdown of RelB gene expression was con-
ﬁrmed by analysis of the target protein by Western blot analysis
(Fig. 3C). In these conditions, we showed that RelB inhibition sig-
niﬁcantly reduces TNF gene expression in unstimulated cells, and
that PACAP has no further effect on TNF gene expression in cells
transfected with RelB siRNA (Fig. 3D). These data indicate that RelB
may be involved in the regulation of the constitutive expression of
TNF and that PACAP inhibits its action.
3.4. RelB is expressed in developing sympathetic neurons
Because the PC12 cell line is considered as a model of sympa-






Fig. 4. Expression of RelB in mouse developing sympathetic ganglia. (A) Immunoﬂuorescence of RelB (green), tyrosine hydroxylase (red) and DAPI (blue) in transverse
sections from E16 mouse embryos. RelB is widely expressed in all structures of the embryos including sympathetic ganglia, which are co-stained with tyrosine hydroxylase
(shown in the box). SG, sympathetic ganglia; DRG, dorsal root ganglia; NC, notochord; NT, neural tube. (B) Sections taken from other ganglia stained for RelB (green), tyrosine
hydroxylase (red) and DAPI (blue).
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sion was analyzed by immunohistochemistry in sympathetic
precursors of E16 mice embryonic paravertebral sympathetic
ganglia (Fig. 4). RelB is indeed expressed in many structures in
mouse embryos, including sympathetic neuroblasts which were
co-labeled by an antibody directed against tyrosine hydroxylase
(Fig. 4). Thus, RelB could play a similar role in sympathetic neuro-
blasts as in PC12 cells.
4. Discussion
The present ﬁndings stem from our initial observation that the
expression of the pro-inﬂammatory cytokine TNF is stronglyreduced during PACAP-induced PC12 cell differentiation. This
effect implied that the cytokine is constitutively expressed in
PC12 cells and that PACAP reduces this expression to be able to
exert its trophic action. PACAP not only inhibited TNF gene expres-
sion, but also signiﬁcantly reduced TNF secretion from PC12 cells,
indicating that the cytokine is indeed constitutively secreted in
basal condition and that PACAP blocks this secretion. Therefore,
the cytokine produced by the sympathetic-like cells could act in
a paracrine and/or autocrine fashion as it has been shown in
microglial cells [13].
In the central and peripheral neurons as in the PC12 cell line,
PACAP exerts a protective activity by inhibiting apoptosis and
increasing cell viability [14,15], as also observed in the present
D.-L. Manecka et al. / FEBS Letters 588 (2014) 3008–3014 3013study. We found that TNF treatment alters both neuroprotection
and neuritogenesis induced by PACAP. This observation correlates
with in vivo studies showing that TNF treatment impairs neuronal
differentiation [16]. Among the two TNF receptors, we showed that
PC12 cells only express TNF-R1 receptor. This receptor, which is
expressed in the developing nervous system [17], possesses a
death domain allowing the induction of caspase activity and apop-
totic cell death upon TNF treatment in different cell types including
PC12 cells [5,18] and our unpublished results]. The fact that TNF
induces caspase activity conﬁrms that the cytokine interferes with
cell survival in PC12 cells as suggested by the MTT assay. Overall,
these observations suggest that constitutive expression and secre-
tion of TNF and its action through TNF-R1 could impede the pro-
differentiation function of PACAP in neuronal cells. Thus, the inhi-
bition of the cytokine by PACAP could represent a prerequisite for
the neuroprotective and differentiating effects of the neuropeptide.
As TNF expression has been shown to be regulated by NF-jB
transcription factor in macrophages [19,20], we used PS-1145,
an inhibitor of NF-jB signaling, in order to determine if this tran-
scription factor is also able to regulate TNF expression in naive or
PACAP-treated PC12 cells. We found that NF-jB activity is neces-
sary for TNF constitutive expression. The inhibition of NF-jB sig-
naling had no further effect on the PACAP-triggered reduction of
TNF gene expression. In fact, TNF mRNA levels were similar in
PACAP- and PS-1145-treated cells, strongly suggesting that
PACAP regulates TNF expression by inhibiting NF-jB activity.
Among the ﬁve subunits of NF-jB, we have previously shown
that PACAP inhibits RelB subunit nuclear translocation, suggest-
ing that this subunit could be involved in PACAP-induced TNF
down regulation [12]. RelB knockdown in PC12 cells showed that
this subunit is indeed required for TNF constitutive expression
and could be responsible for PACAP-induced TNF inhibition.
These observations are in line with previous results obtained in
immune cells showing that the RelB subunit of NF-jB is able to
bind jB regulatory sites of the TNF gene promoter, and that the
absence of this subunit in RelB-deﬁcient animals results in a
impaired production of TNF by macrophages in response to cyto-
kines [21]. Furthermore, RelB-containing complexes participate in
the constitutive jB activity observed in lymphoid tissues [22,23].
In macrophages, PACAP-induced inhibition of TNF expression has
been ascribed to (i) reduction of IKK activity and NF-jB nuclear
translocation and (ii) competition between NF-jB and PACAP-
induced CREB for their common coactivator, the CRE-binding pro-
tein, leading to an overall decrease in NF-jB activity and TNF
expression [24]. Similar mechanisms could occur in PC12 cells
to mediate the effect of PACAP on TNF expression and the resul-
tant action of the cytokine. Indeed, PACAP inhibits RelB nuclear
translocation [12] and stimulates CREB activity in PC12 cells
[25]. Interestingly, immunohistochemical analysis of sympathetic
ganglia in mouse embryos revealed the expression of RelB in
developing sympathetic neurons, suggesting that RelB could be
involved in TNF expression in vivo. The production of the cyto-
kine has previously been demonstrated in sympathetic neuro-
blasts, where it induced apoptosis [17].
Our data show that constitutive activity of the RelB subunit
within NF-jB is required for constitutive expression of TNF in
PC12 cells. The cytokine is secreted by PC12 cells and interacts
with TNF-R1 to induce apoptotic cell death. Down-regulation of
TNF gene expression by PACAP via RelB inhibition would be among
the trophic effects of the neuropeptide, acting through inhibition of
the apoptotic and anti-differentiation actions of the cytokine.
These data suggest that TNF autocrine/paracrine effects in vivo
could be implicated in the death of symapathetic neuroblasts that
fail to obtain sufﬁcient PACAP, as has been shown for nerve growth
factor-dependent neurons during sympathetic neuron develop-
ment [17].Acknowledgments
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